Regeneron Pharmaceuticals (REGN) announced Tuesday that sales of its new drug, Eylea, were between $24 million and $24 million during the fourth quarter.
Regeneron Pharmaceuticals gapped open sharply higher Tuesday, but moved in a narrow range throughout the session. The stock finished up by 8.96 at $74.44 and closed challenging the highs of the year, trading at a 3 1/2 month high.
For comments and feedback: editorial@rttnews.com